IP Library Granted Patent US 10,947,222
Granted Patent B2
US 10,947,222 · App. 16/461,880 · Granted Mar 16, 2021

Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Inventors: Dong-Ming Shen (Edison, NJ); Thomas H. Graham (Quincy, MA); Jinlong Jiang (Scotch Plains, NJ); Fa-Xiang Ding (Staten Island, NY); Clare Tudge (Wayne, PA)
Assignee: Merck Sharp & Dohme Corp.
C07D409/12A61K31/404A61K31/4439A61K31/506A61K45/06A61P1/16C07D209/08C07D209/10C07D401/12C07D409/14C07D413/12C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,947,222
App. No.
16/461,880
Granted
Mar 16, 2021
Kind
B2
Abstract

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Claims (121)

1. A compound having structural Formula I:

or a pharmaceutically acceptable salt thereof wherein:

R 1 is

(1) aryl unsubstituted or substituted by 1-3 R 5 , or

(2) 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted by 1-3 R 5 , or

(3) 8- to 10-membered fused heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted by 1-3 R 5 ;

R 2 is

R 3 is

(1) —(C 1-6 )alkyl-O—(C 1-3 )alkyl,

(2) 4- to 7-membered monocyclic or 6- to 10-membered bicyclic heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is unsubstituted or substituted by 1-3 R 7 ,

(3) —(C 1-6 )alkyl-heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O, and S, and wherein the heterocyclyl is a 5- to 7-membered ring, or

(4) —(C 1-6 )alkyl-pyridinyl, wherein the pyridinyl is unsubstituted or substituted with (C 1-3 )alkyl or halo(C 1-3 )alkyl, and wherein the alkyl is unsubstituted or substituted with a hydroxy;

R 4 is

(1) hydrogen,

(2) (C 1-3 )alkyl, or

(3) CN;

each R 5 is

(1) halo,

(2) (C 1-3 )alkyl,

(3) halo(C 1-3 )alkyl,

(4) (C 3-6 )cycloalkyl,

(5) —C(O)NH 2 ,

(6) —C(O)O(C 1-3 )alkyl,

(7) (C 1-3 )alkoxy,

(8) halo(C 1-3 )alkoxy,

(9) hydroxy,

(10) phenyl,

(11) —NHC(O)CH 3 ,

(12) 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted by 1-2 (C 1-3 )alkyl, or hydroxy,

(13) CN,

(14) hydroxy(C 1-3 )alkyl, or

(15) (C 1-3 )alkyl-heterocyclyl, wherein the heterocyclyl contains 1 or 2 heteroatoms independently selected from N, O, or S, and wherein the heterocyclyl is a 5- to 7-membered ring;

each R 6 is

(1) hydrogen, or

(2) halo;

each R 7 is

(1) oxo, or

(2) (C 1-3 )alkyl;

X is CH or N;

Y is CH or N;

n is 1 or 2.

2. The compound of claim 1 , wherein R 3 is —(C 1-6 )alkyl-O—(C 1-3 )alkyl; a 5- to 7-membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is unsubstituted or substituted by 1-3 R 7 ; or —(C 1-6 )alkyl-heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O, and S, and wherein the heterocyclyl is a 5- to 7-membered ring, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein R 2 is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2 , wherein R 3 is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , wherein R 2 is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 4 , wherein R 3 is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , wherein R 2 is

or a pharmaceutically acceptable salt thereof.

8. The compound claim 1 , wherein R 2 is

or a pharmaceutically acceptable salt thereof.

9. A compound of claim 1 , selected from the group consisting of

(1) 3-(2-chlorophenyl)-1-(4-fluorophenyl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(2) 3-(2-Chlorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(3) 3-(2-chlorophenyl)-1-(4-fluorophenyl)-N-(1-methoxypropan-2-yl)-1H-indole-6-carboxamide,

(4) 3-(2-chlorophenyl)-1-(4-fluorophenyl)-N-(2-methyl-1-morpholinopropan-2-yl)-1H-indole-6-carboxamide,

(5) (S)-3-(2-chlorophenyl)-1-(4-fluorophenyl)-N-(2-hydroxy-1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1H-indole-6-carboxamide,

(6) (S)-3-(2-chlorophenyl)-1-(4-fluorophenyl)-N-(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1H-indole-6-carboxamide

(7) (R)-3-(2-chlorophenyl)-1-(4-fluorophenyl)-N-(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1H-indole-6-carboxamide,

(8) 3-(2-chlorophenyl)-1-(4-fluorophenyl)-2-methyl-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(9) 3-(2-chlorophenyl)-2-cyano-1-(4-fluorophenyl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(10) 3-(3-(difluoromethoxy)phenyl)-1-(5-fluoropyridin-2-yl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(11) 3-(3-cyclopropylphenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(5-fluoropyridin-2-yl)-1H-indole-6-carboxamide,

(12) 3-(3-cyclopropylphenyl)-1-(5-fluoropyridin-2-yl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(13) 3-(3-(difluoromethoxy)phenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(5-fluoropyridin-2-yl)-1H-indole-6-carboxamide,

(14) 3-(2-chlorophenyl)-1-(5-fluoropyridin-2-yl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(15) 3-(2-chlorophenyl)-1-(5-fluoropyrimidin-2-yl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(16) 3-(3-cyclopropylphenyl)-1-(5-fluoropyrimidin-2-yl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(17) 3-(3-cyclopropylphenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(5-fluoropyrimidin-2-yl)-1H-indole-6-carboxamide,

(18) 3-(3-(difluoromethoxy)phenyl)-1-(5-fluoropyrimidin-2-yl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(19) 3-(3-(difluoromethoxy)phenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(5-fluoropyrimidin-2-yl)-1H-indole-6-carboxamide,

(20) 3-(4,6-dimethylpyridin-2-yl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(21) 3-(4-chloropyridin-2-yl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(22) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(pyridin-2-yl)-1H-indole-6-carboxamide,

(23) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(4-methylpyridin-2-yl)-1H-indole-6-carboxamide,

(24) 1-(4-fluorophenyl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-3-(4-methylpyridin-2-yl)-1H-indole-6-carboxamide,

(25) 3-(5-(difluoromethoxy)pyridin-3-yl)-1-(4-fluorophenyl)-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(26) 3-(3-Cyclopropylphenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(27) 3-(3-(difluoromethoxy)phenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(28) 3-(3-(difluoromethoxy)phenyl)-1-(4-fluorophenyl)-2-methyl-N-(3-methyl-1,1-dioxidotetrahydrothiophen-3-yl)-1H-indole-6-carboxamide,

(29) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(2-methoxyphenyl)-1H-indole-6-carboxamide,

(30) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-[3-(trifluoromethyl)phenyl]-1H-indole-6-carboxamide,

(31) 3-(3-chlorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(32) methyl 3-{6-[(1,1-dioxidotetrahydrothiophen-3-yl)carbamoyl]-1-(4-fluorophenyl)-1H-indol-3-yl}benzoate,

(33) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(3-methoxyphenyl)-1H-indole-6-carboxamide,

(34) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(3-methylphenyl)-1H-indole-6-carboxamide,

(35) N-(1,1-dioxidotetrahydrothiophen-3-yl)-3-(3-fluorophenyl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(36) 3-biphenyl-3-yl-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(37) 3-[3-(acetylamino)phenyl]-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(38) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-[3-(1H-pyrazol-1-yl)phenyl]-1H-indole-6-carboxamide,

(39) 3-[3-(difluoromethoxy)phenyl]-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(40) N-(1,1-dioxidotetrahydrothiophen-3-yl)-3-(2-fluorophenyl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(41) 3-(3,5-dichlorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(42) 3-[2-(difluoromethoxy)phenyl]-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(43) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-phenyl-1H-indole-6-carboxamide,

(44) 3-(2,3-dichlorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(45) 3-(3-cyanophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(46) 3-(3-cyclopropylphenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(47) 3-(2,6-dichlorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(48) 3-(2,6-difluorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(49) 3-(2-chloro-6-fluorophenyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(50) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-pyrimidin-5-yl-1H-indole-6-carboxamide,

(51) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1′-methyl-1H,1′H-3,5′-biindole-6-carboxamide,

(52) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-pyridin-3-yl-1H-indole-6-carboxamide,

(53) 3-(3,5-dimethylisoxazol-4-yl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(54) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-indole-6-carboxamide,

(55) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(4-methylphenyl)-1H-indole-6-carboxamide,

(56) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-[4-(1H-pyrazol-1-yl)phenyl]-1H-indole-6-carboxamide,

(57) 3-[4-(difluoromethoxy)phenyl]-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide,

(58) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-[3-(trifluoromethoxy)phenyl]-1H-indole-6-carboxamide,

(59) N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-3-(3-hydroxyphenyl)-1H-indole-6-carboxamide,

(60) methyl 4-{6-[(1,1-dioxidotetrahydrothiophen-3-yl)carbamoyl]-1-(4-fluorophenyl)-1H-indol-3-yl}thiophene-2-carboxylate, and

(61) 3-[3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-N-(1,1-dioxidotetrahydrothiophen-3-yl)-1-(4-fluorophenyl)-1H-indole-6-carboxamide;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A method of treating atherosclerosis, hepatic steatosis, atherosclerosis, type-2 diabetes mellitus, obesity, hyperlipidemia, non-alcoholic steatohepatitis or hypercholesterolemia in a patient in need of treatment comprising the administration to the patient of a therapeutically effective amount of a compound of claim 1 .

12. The method according to claim 11 for treating atherosclerosis.

13. The method according to claim 11 for treating non-alcoholic steatohepatitis.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2019
From: SHEN, DONG-MING; GRAHAM, THOMAS H.; JIANG, JINLONG; DING, FA-XIANG; TUDGE, CLARE
To: MERCK SHARP & DOHME CORP.
Reel/Frame 049209/0097 →